Lian Chen1, Rui Chen1, Zhe Zhu1, Yichen Zhang1, Zhengwei Wen1, Yun Li1, Xiaoming Li1, Yuwen Luo1, Liyu Ma1, Shuguang Lin1, Xin Chen1. 1. 1 Southern Medical University, Guangzhou 510515, China ; 2 Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China ; 3 Department of Respiratory Diseases, SUN Yat-sen Memorial Hospital, SUN Yat-sen University, Guangzhou 510120, China ; 4 Department of Respiratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China.
Abstract
PURPOSE: A number of different clinical characteristics have been reported to singly correlate with therapeutic activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in advanced non-small-cell lung cancer (NSCLC). This study aimed to identify predictive factors associated with prognostic benefits of gefitinib. PATIENTS AND METHODS: EGFR gene typing in 33 advanced NSCLC patients received gefitinib (250 mg/day) were analyzed with mutant-enriched PCR assay. Gefitinib response was evaluated with potential predictive factors retrospectively. RESULTS: The overall objective response rate (ORR) and median progression-free survival (PFS) in the 33 patients treated by gefitinib were 45.5% and 3.0 (2.0-4.0) months. The ORR and median PFS in EGFR gene mutation patients were significantly higher/longer than those in EGFR gene wild-type patients (P<0.01). Similarly, the ORR and median PFS in non-smoker patients were significantly higher/longer than those in smoker patients (P<0.05, P<0.01, respectively). However, no difference for ORR and median PFS occurred between male and female patients. Logistic multivariate analysis showed that only EGFR mutated gene was significantly associated with the ORR (P<0.01). Both EGFR mutated gene and non-smoker were the major factors that contributed to PFS (P<0.05). CONCLUSIONS: EGFR mutated gene and non-smoker status are potential predictors for gefitinib response in NSCLC patients.
PURPOSE: A number of different clinical characteristics have been reported to singly correlate with therapeutic activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in advanced non-small-cell lung cancer (NSCLC). This study aimed to identify predictive factors associated with prognostic benefits of gefitinib. PATIENTS AND METHODS: EGFR gene typing in 33 advanced NSCLCpatients received gefitinib (250 mg/day) were analyzed with mutant-enriched PCR assay. Gefitinib response was evaluated with potential predictive factors retrospectively. RESULTS: The overall objective response rate (ORR) and median progression-free survival (PFS) in the 33 patients treated by gefitinib were 45.5% and 3.0 (2.0-4.0) months. The ORR and median PFS in EGFR gene mutation patients were significantly higher/longer than those in EGFR gene wild-type patients (P<0.01). Similarly, the ORR and median PFS in non-smoker patients were significantly higher/longer than those in smoker patients (P<0.05, P<0.01, respectively). However, no difference for ORR and median PFS occurred between male and female patients. Logistic multivariate analysis showed that only EGFR mutated gene was significantly associated with the ORR (P<0.01). Both EGFR mutated gene and non-smoker were the major factors that contributed to PFS (P<0.05). CONCLUSIONS:EGFR mutated gene and non-smoker status are potential predictors for gefitinib response in NSCLCpatients.
Authors: Hisayuki Shigematsu; Li Lin; Takao Takahashi; Masaharu Nomura; Makoto Suzuki; Ignacio I Wistuba; Kwun M Fong; Huei Lee; Shinichi Toyooka; Nobuyoshi Shimizu; Takehiko Fujisawa; Ziding Feng; Jack A Roth; Joachim Herz; John D Minna; Adi F Gazdar Journal: J Natl Cancer Inst Date: 2005-03-02 Impact factor: 13.506
Authors: Lecia V Sequist; Renato G Martins; David Spigel; Steven M Grunberg; Alexander Spira; Pasi A Jänne; Victoria A Joshi; David McCollum; Tracey L Evans; Alona Muzikansky; Georgiana L Kuhlmann; Moon Han; Jonathan S Goldberg; Jeffrey Settleman; A John Iafrate; Jeffrey A Engelman; Daniel A Haber; Bruce E Johnson; Thomas J Lynch Journal: J Clin Oncol Date: 2008-05-05 Impact factor: 44.544
Authors: Lecia V Sequist; Victoria A Joshi; Pasi A Jänne; Alona Muzikansky; Panos Fidias; Matthew Meyerson; Daniel A Haber; Raju Kucherlapati; Bruce E Johnson; Thomas J Lynch Journal: Oncologist Date: 2007-01
Authors: Chen He; Ming Liu; Chengzhi Zhou; Jiexia Zhang; Ming Ouyang; Nanshan Zhong; Jun Xu Journal: Int J Cancer Date: 2009-11-15 Impact factor: 7.396
Authors: M Satouchi; S Negoro; Y Funada; Y Urata; T Shimada; S Yoshimura; Y Kotani; T Sakuma; H Watanabe; S Adachi; Y Takada; Y Yatabe; T Mitsudomi Journal: Br J Cancer Date: 2007-03-27 Impact factor: 7.640